Ovarian Cancer Stage III
14 clinical trials · Condition
◉ Watch Ovarian Cancer Stage III
| Record | Firm | Date |
|---|---|---|
| Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (NCT04997096) | Dana-Farber Cancer Institute | 2022-04-02 |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer (NCT05187208) | Seoul National University Hospital | 2022-01-01 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (NCT04938583) | CanariaBio Inc. | 2021-03-17 |
| Prehabilitation in Gynaecological Cancer Patients (NCT04789694) | Charles University, Czech Republic | 2021-01-25 |
| Self-Advocacy Serious Game in Advanced Cancer (NCT03339765) | University of Pittsburgh | 2018-12-13 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (NCT03162562) | CanariaBio Inc. | 2017-05-30 |
Track Ovarian Cancer Stage III automatically
Every clearance here is in the API, with alerts when new ones post.